曲美他嗪联合贝那普利治疗舒张性心力衰竭的临床疗效及安全性评价

Clinical efficacy and safety of benazepril combined with trimetazidine in the treatment of diastolic heart failure

目的评价曲美他嗪单独或联合贝那普利治疗舒张性心力衰竭的临床疗效及安全性。方法将74例舒张性心力衰竭患者随机分为对照组36例和试验组38例。对照组予以曲美他嗪20 mg,tid,po,连续服用1个月;试验组在对照组的基础上,加用贝那普利10 mg,qd,po,连续服用1个月。疗程结束后,观察2组患者心功能改善情况及服药期间的不良反应发生率。结果试验组总有效率94.74%(36/38)显著高于对照组77.78%(28/36,P<0.05)。与治疗前比较,2组患者治疗1个月后舒张早期血流峰速率(E)显著升高,舒张晚期血流峰速率(A)显著降低,E/A值显著升高(P<0.05)。治疗1个月后,试验组E及E/A值显著高于对照组,A值显著低于对照组(P<0.05)。2组患者治疗期间均无不良反应发生。结论曲美他嗪联合贝那普利治疗舒张性心力衰竭可提高患者的临床疗效。

Objective To evaluate the clinical efficacy and safety of benazepril combined with trimetazidine in the treatment of diastolic heart failure.Methods Seventy-four patients with diastolic heart failure were included in this study from February 2012 to June 2014 in our hospital.And the included 74 patients were randomly divided into control group（n = 36） and treatment group（n = 38）.Patients included in the control group were given trimetazidine 20 mg,tid,po with 1 month.Patients in the treatment group were given trimetazidine 20 mg,tid,po plus benazepril 10 mg,qd,po with 1 month.The clinical efficacy and adverse drug reactions were observed and compared between the two groups.Results The total efficacy were 77.78%（28 /36） and 94.74%（36 /38） in the control and treatment group respectively with treatment group statistical higher than the control group（P 〈 0.05）.Late diastolic blood flow peak rate（A）,early diastolic blood flow peak rate（E） and E / A value were significant improved after treatment（P 〈 0.05）.And the A,E and E / A value in the treatment group were significant better than in the control group after 1 month treatment（P 〈 0.05）.During treatment,there was not adverse drug reactions happened in two groups.Conclusion Benazepril combined with trimetazidine can significant improve the clinical efficacy of diastolic heart failure.